Comparative Pharmacology
Head-to-head clinical analysis: TAZAROTENE versus TEGISON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZAROTENE versus TEGISON.
TAZAROTENE vs TEGISON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
Retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell differentiation, proliferation, and apoptosis. It reduces epidermal proliferation and promotes normal keratinization.
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
Initial dose: 0.5-1 mg/kg/day orally, divided twice daily; maintenance dose: 0.3-0.5 mg/kg/day. Maximum dose: 1.5 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateTazarotene + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Nilotinib
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Terminal elimination half-life is approximately 120-168 hours (5-7 days) due to extensive tissue storage; clinical effects persist for weeks after discontinuation.
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Primarily renal (60-80% as metabolites) and biliary/fecal (15-25% as unchanged drug and metabolites).
Category D/X
Category C
Retinoid
Retinoid
"The metabolism of Nilotinib can be decreased when combined with Tazarotene."